Clinical trialNCT06625073RecruitingPhase 4Interventional

Randomized Trial of SGLT2i in Heart Transplant Recipients

SponsorVA Office of Research and DevelopmentEnrollment200Cardiovascular DiseaseHeart TransplantKidney Disease

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Heart transplant (HTx) is an established therapy for advanced heart disease that restores quality of life and improves survival. However, due to preexisting comorbidities combined with the immunosuppressive therapies required after transplantation, HTx recipients remain at high risk for kidney, cardiovascular (CV), and metabolic disease. Large randomized clinical trials have recently shown that sodium-glucose cotransporter 2 inhibitors (SGLT2i) have potent kidney protective and CV benefits in many populations of patients with chronic kidney disease (CKD), CV disease and/or diabetes. SGLT2i have not been studied prospectively in HTx recipients, which represents a barrier to their use in this population. In this multicenter randomized controlled trial in Veterans with HTx, investigators will evaluate the potential benefits of empagliflozin on kidney function, cardiometabolic risk, erythropoiesis, and functional status. A total of 200 Veterans will be randomly assigned to receive either empagliflozin 10 mg daily or a matching placebo for 12 months.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Josef Stehlik, MD MPH
VA Salt Lake City Health Care System, Salt Lake City, UT
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Va Palo Alto Health Care System, Palo Alto, Ca
Palo Alto, California, United States
Not, yet, recruiting
Tennessee Valley Healthcare System Nashville Campus, Nashville, Tn
Nashville, Tennessee, United States
Not, yet, recruiting
Michael E. Debakey Va Medical Center, Houston, Tx
Houston, Texas, United States
Not, yet, recruiting
Va Salt Lake City Health Care System, Salt Lake City, Ut
Salt Lake City, Utah, United States
Josef Stehlik, MD MPH →
Recruiting
Hunter Holmes Mcguire Va Medical Center, Richmond, Va
Richmond, Virginia, United States
Not, yet, recruiting
William S. Middleton Memorial Veterans Hospital, Madison, Wi
Madison, Wisconsin, United States
Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Empagliflozin →Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 20 Jan 2026
Primary completion: 31 Aug 2029
Completion: 28 Feb 2030
Last update posted: 22 Jan 2026
Registered enrollment: 200
Registry id: NCT06625073

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.